Adrecizumab in Cardiogenic Shock
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.
Also called NCT03989531
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 150 participants
- Sponsor
- Dr. med. Mahir Karakas
- Registry
-
NCT03989531
-
- Other papers using this trial's data
- Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT03989531. Randomized; quadruple masking; primary purpose treatment. Start 2019-04-04 (actual); primary completion 2021-04-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Adrecizumab in Cardiogenic Shock
- Acronym
- ACCOST-HH
- Condition
- Cardiogenic Shock
- Condition
- Endothelial Dysfunction
- Intervention (Biological)
- Adrecizumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Dr. med. Mahir Karakas
Record details
- Record id
cardio:ct-nct03989531- Content hash
259e166a4a95af0c53674665ee7f5d6dee9acffdb93146164156ba52d9c01653